Monoclonal Antibodies and recombinant fragments for therapeutic and diagnostic applications Anticorpi monoclonali e frammenti ricombinanti per applicazioni terapeutiche e diagnostiche
Contact person Contatto: Annamaria Sandomenico, annamaria.sandomenico
gmail.com
Actors Attori: Annamaria Sandomenico, annamaria.sandomenicogmail.com, Menotti Ruvo, menotti.ruvounina.it, Nunzianna Doti, nunzia.dotigmail.com,
Research areas Aree di ricerca: Molecules of immunologic interest Molecole di interesse immunologico,
Keywords Parole chiave: Monoclonal antibody, Recombinant Fragment, Fab, scFv, ADC, Antibody humanization, CART
Contact person Contatto: Annamaria Sandomenico, annamaria.sandomenico
gmail.comActors Attori: Annamaria Sandomenico, annamaria.sandomenico
gmail.com, Menotti Ruvo, menotti.ruvounina.it, Nunzianna Doti, nunzia.dotigmail.com, Description Descrizione:
MonoclonalAntibodies (mAb) are biomolecules with high specificity and affinity and in principle can be raised against any antigen [1]. Antibodies are made of structural modules that can be isolated from the original molecule or recombinantly produced to obtain new functional formats with tailored biochemical, biophysical and functional properties. The modular nature of immunoglobulins is continuously exploited to engineer“customized” therapeutics with pharmacologic properties optimized for specific diagnostic and therapeutic applications. Half-life, biodistribution, valency, affinity, avidity, tissue penetration and bioactivity can each be controlled by selecting and combining appropriate modular domains with defined structural features, allowing a tight control over both safety and efficacy of antibody products. Antibodies fragments in several new formats are routinely investigated to increase their specificity and therapeutic efficacy and to achieve site-specific functionalizations with reporters and other payloads to generate innovative diagnostic reagents and Antibody Drug Conjugates (ADC) [2, 3].
Gli anticorpi monoclonali (mAb)sono biomolecole con elevata specificità e affinità e in principio possono essere ottenuti contro qualsiasi antigene [1]. Gli anticorpi sono costituiti da moduli strutturali ben definiti che possono essere isolati dalla molecola originale o riprodotti in forma ricombinante per realizzare nuovi format con proprietà biochimiche, biofisiche e funzionali predefinite. Tali domini modulari sono sfruttati per generare nuove biomolecole di natura anticorpale con proprietà farmacologiche ottimizzate per specifiche applicazioni diagnostiche e terapeutiche. Proprietà come emivita, biodistribuzione, valenza, affinità, avidità, penetrazione dei tessuti e bioattività possono essere controllate ciascuna selezionando e combinando domini appropriati con caratteristiche strutturali definite che permettono di modulare sia la sicurezza che efficacia dei prodotti anticorpali.
MonoclonalAntibodies (mAb) are biomolecules with high specificity and affinity and in principle can be raised against any antigen [1]. Antibodies are made of structural modules that can be isolated from the original molecule or recombinantly produced to obtain new functional formats with tailored biochemical, biophysical and functional properties. The modular nature of immunoglobulins is continuously exploited to engineer“customized” therapeutics with pharmacologic properties optimized for specific diagnostic and therapeutic applications. Half-life, biodistribution, valency, affinity, avidity, tissue penetration and bioactivity can each be controlled by selecting and combining appropriate modular domains with defined structural features, allowing a tight control over both safety and efficacy of antibody products. Antibodies fragments in several new formats are routinely investigated to increase their specificity and therapeutic efficacy and to achieve site-specific functionalizations with reporters and other payloads to generate innovative diagnostic reagents and Antibody Drug Conjugates (ADC) [2, 3].
In the last decade, we have developed mAbs against several protein targets [4-12] including tumours biomarkers and therapeutic targets for several diseases like Cripto-1, Nodal, theE2 protein of HCV, Ape1 and PRAME. In the last years,
we have also set up a bacterial expression platform for generating
ad hoc
engineered recombinant Fabs and scFv fragments [13] that bear reactive sites for their site-specific modification and multimerization using Microbial Transglutaminaseenzyme (MTG) [14,15]. The platform has been validated using the anti-Her2monoclonal antibody trastuzumab obtaining multimeric recombinant variants of the trastuzumab Fab and scFv. Bispecific humanized Fab2 with affinities similar or superior to the full-lenght antibodies have been also obtained using anti-Cripto-1 and anti Nodal Fabs. Site-specific labelling with dyes/fluorophores or cytotoxic payloads are similarly achieved by direct functionalization or decorating 100 nm nanoparticles made of human albumin loaded with cytotoxic agents, thus obtaining highly innovative 2
nd
generation ADCs. Biochemical and biophysical studies of scFv fragments against relevant therapeutic targets are also underway to support the design of CART systems.
I frammenti anticorpali, nelle numerosi e innovative combinazioni, sono costantemente utilizzati per incrementarela specificità di azione e l’efficacia terapeutica per ottenere funzionalizzazioni sito-specifiche con reporter e altri payloads per generarere agenti diagnostici innovativi e nuovi bioterapeutici anticorpo - farmacoconiugati (ADC) [2, 3].
Nell'ultimo decennio abbiamo sviluppato numerosi anticorpi monoclonali contro differenti target proteici [4-12]inclusi nuovi biomarcatori tumorali e bersagli terapeutici per diverse patologie come Cripto-1, Nodal, la proteina E2 di HCV, Ape1 e PRAME.
Negli ultimi anni abbiamo allestito una piattaforma di espressione batterica per generare frammenti Fab ricombinantie scFv ingegnerizzati
ad hoc
con siti reattivi per la bioconiugazione sito-specifica [13] e la multimerizzazione utilizzando l'enzima transglutaminasi (MTGase) [14,15].
La piattaforma è stata validata impiegando l'anticorpo monoclonale anti-Her2 trastuzumab ottenendo varianti ricombinanti multimeriche dei frammenti Fab ed scFv dell’anticorpo [13].
Fab
2
bispecifici con affinità simili o superiori agli stessi anticorpi monoclonali sono stati ottenuti utilizzando frammenti Fab ricombinanti umanizzati anti-Cripto-1 e anti-Nodal.Tali frammenti sono stati marcati in maniera sito-specifica con diversi traccianti e anche usati per decorare nanoparticelle da 100 nm di albumina umana caricate con agenti citotossici, ottenendo così ADC di seconda generazione in formulazioni altamente innovativi. Sono inoltre in corso studibiochimici e biofisici di frammenti scFv contro bersagli terapeutici rilevanti per supportare la progettazione di sistemi CART.
Selected papers Lavori selezionati:
[1] Sivaccumar J, Sandomenico A, Vitagliano L, Ruvo M.Monoclonal antibodies: A prospective and retrospective view.
Curr Med Chem. 2020 Feb 19. doi: 10.2174/0929867327666200219142231.
[2] Selis F, Focà G, Sandomenico A, Marra C, Di MauroC, Saccani Jotti G, Scaramuzza S, Politano A, Sanna R, Ruvo M, Tonon G.Pegylated Trastuzumab Fragments Acquire an Increased in Vivo Stability but Showa Largely Reduced Affinity for the Target Antigen
Int J Mol Sci. 2016 Apr 1;17(4):491. doi:10.3390/ijms17040491.
[3] Sandomenico A, Sivaccumar JP, Ruvo M. Evolution ofEscherichia coli Expression System in Producing Antibody Recombinant Fragments.Int J Mol Sci. 2020 Aug 31;21(17):6324. doi: 10.3390/ijms21176324.
[4] Focà G, Iaccarino E, Focà A, Sanguigno L,Untiveros G, Cuevas-Nunez M, Strizzi L, Leonardi A, Ruvo M, Sandomenico A.Development of conformational antibodies targeting Cripto-1 with neutralizingeffects in vitro. Biochimie. 2019Mar;158:246-256. doi: 10.1016/j.biochi.2019.01.016. Epub 2019 Jan 28.
[5] Canassa-DeLeo T, Campo VL, Rodrigues LC, MarchioriMF, Fuzo C, Brigido MM, Sandomenico A, Ruvo M, Maranhão AQ, Dias-Baruffi M.Multifaceted antibodies development against synthetic α-dystroglycan mucinglycopeptide as promising tools for dystroglycanopathies diagnostic. GlycoconjJ. 2020 Feb;37(1):77-93. doi: 10.1007/s10719-019-09893-z. Epub 2019 Dec 10.
[6] Calvanese L, Focà A, Sandomenico A, Focà G,Caporale A, Doti N, Iaccarino E, Leonardi A, D'Auria G, Ruvo M, Falcigno L.Structural insights into the interaction of a monoclonal antibody and Nodalpeptides by STD-NMR spectroscopy. Bioorg Med Chem. 2017 Dec15;25(24):6589-6596. doi: 10.1016/j.bmc.2017.10.036. Epub 2017 Oct 28.
[7] Sandomenico A, Focà A, Sanguigno L, Caporale A,Focà G, Pignalosa A, Corvino G, Caragnano A, Beltrami AP, Antoniali G, Tell G,Leonardi A, Ruvo M. Monoclonal antibodies against pools of mono- andpolyacetylated peptides selectively recognize acetylated lysines within thecontext of the original antigen. MAbs. 2016 Nov/Dec;8(8):1575-1589. doi:10.1080/19420862.2016.1225643. Epub 2016 Aug 25.
[8] Sandomenico A, Leonardi A, Berisio R, Sanguigno L,Focà G, Focà A, Ruggiero A, Doti N, Muscariello L, Barone D, Farina C, OwsiankaA, Vitagliano L, Patel AH, Ruvo M. Generation and Characterization ofMonoclonal Antibodies against a Cyclic Variant of Hepatitis C Virus E2 Epitope412-422. J Virol. 2016 Jan 27;90(7):3745-59. doi: 10.1128/JVI.02397-15
[9] Strizzi L, Sandomenico A, Margaryan NV, Focà A,Sanguigno L, Bodenstine TM, Chandler GS, Reed DW, Gilgur A, Seftor EA, SeftorRE, Khalkhali-Ellis Z, Leonardi A, Ruvo M, Hendrix MJ. Effects of a novelNodal-targeting monoclonal antibody in melanoma. Oncotarget. 2015 Oct27;6(33):34071-86. doi: 10.18632/oncotarget.6049.
[10] Focà A, Sanguigno L, Focà G, Strizzi L, IannittiR, Palumbo R, Hendrix MJ, Leonardi A, Ruvo M, Sandomenico A. New Anti-NodalMonoclonal Antibodies Targeting the Nodal Pre-Helix Loop Involved in Cripto-1Binding. Int J Mol Sci. 2015 Sep 7;16(9):21342-62. doi: 10.3390/ijms160921342.
[11] Sandomenico A, Ruvo M. Targeting Nodal andCripto-1: Perspectives Inside Dual Potential Theranostic CancerBiomarkers. Curr Med Chem.2019;26(11):1994-2050. doi: 10.2174/0929867325666180912104707.
[12] Sivaccumar JP, Leonardi A, Iaccarino E, Corvino G, Sanguigno L, Chambery A, Russo R, Valletta M, Latino D, Capasso D, Doti N, Ruvo M, Sandomenico A . Devolopment of a New Highly Selective Monoclonal Antibody against Preferentially Expressed Antigen in Melanoma (PRAME) and identification of the Target Epitope by Bio_Layer Interferometry Int J Mol Sci. 2021 Mar 20;22(6):3166. doi: 10.3390/ijms22063166.
[ 14 ] Caporale A, Selis F, Sandomenico A, Jotti GS,Tonon G, Ruvo M. The LQSP tetrapeptide is a new highly efficient substrate ofmicrobial transglutaminase for the site-specific derivatization of peptides andproteins. Biotechnol J. 2015Jan;10(1):154-61. doi: 10.1002/biot.201400466. Epub 2014 Dec 16.
[15] Doti N, Caporale A, Monti A, Sandomenico A, SelisF, Ruvo M. A recent update on the use of microbial transglutaminase for thegeneration of biotherapeutics. World J Microbiol Biotechnol, 2020, 36, (4), 53.
Monoclonal Antibodies and recombinant fragments for therapeutic and diagnostic applications Anticorpi monoclonali e frammenti ricombinanti per applicazioni terapeutiche e diagnostiche
| ▼ Biomolecole in grado di modulare l’angiogenesi VEGF-dipendente Biomolecules able to modulate the VEGF-dependent angiogenesis |
Monoclonal Antibodies and recombinant fragments for therapeutic and diagnostic applications Anticorpi monoclonali e frammenti ricombinanti per applicazioni terapeutiche e diagnostiche
Search related bibliography on PubMed Cerca bibliografia collegata su PubMed
Camorani S, Passariello M, Agnello L, Esposito S, Collina F, Cantile M, Di Bonito M, Ulasov IV, Fedele M, Zannetti A, De Lorenzo C, Cerchia L
* Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer (68 visite) (PDF 37 visite)
J Exp Clin Cancer Res (ISSN: 0392-9078linking), 2020 Sep 7; 39(1): 180-180.
Impact Factor: 7.068
Dettagli Esporta in BibTeX Esporta in EndNote
Sandomenico A, Sivaccumar JP, Ruvo M
* Evolution of Escherichia coli Expression System in Producing Antibody Recombinant Fragments (36 visite)
Int J Mol Sci (ISSN: 1422-0067linking), 2020 Aug 31; 21(17): N/D-N/D.
Impact Factor: 4.556
Dettagli Esporta in BibTeX Esporta in EndNote
Bertani L, Caviglia GP, Antonioli L, Pellicano R, Fagoonee S, Astegiano M, Saracco GM, Bugianesi E, Blandizzi C, Costa F, Ribaldone DG
* Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases (84 visite)
J Clin Med (ISSN: 2077-0383electronic, 2077-0383linking), 2020 May 2; 9(5): N/D-N/D.
Impact Factor: 6.78
Dettagli Esporta in BibTeX Esporta in EndNote
Sivaccumar J, Sandomenico A, Vitagliano L, Ruvo M
* Monoclonal antibodies: A prospective and retrospective view (33 visite)
Curr Med Chem (ISSN: 0929-8673linking), 2020 Feb 19; N/D: N/D-N/D.
Impact Factor: 4.184
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, Kellner M, Esposito D, Liesche-starnecker F, Bua S, Supuran CT, Monti SM, Zeidler R, De Simone G
* Biochemical and structural insights into Carbonic Anhydrase XII/Fab6A10 complex (133 visite)
J Mol Biol (ISSN: 0022-2836linking, 1089-8638), 2019 Dec 6; 431(24): 4910-4921.
Impact Factor: 5.067
Dettagli Esporta in BibTeX Esporta in EndNote
Supuran CT, Alterio V, Di Fiore A, D'Ambrosio K, Carta F, Monti SM, De Simone G
* Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: Three for the price of one (250 visite)
Med Res Rev (ISSN: 1098-1128electronic, 0198-6325linking), 2018 Sep; 38(6): 1799-1836.
Impact Factor: 8.29
Dettagli Esporta in BibTeX Esporta in EndNote
Calvanese L, Foca A, Sandomenico A, Foca G, Caporale A, Doti N, Iaccarino E, Leonardi A, D'Auria G, Ruvo M, Falcigno L
* Structural insights into the interaction of a monoclonal antibody and Nodal peptides by STD-NMR spectroscopy (453 visite)
Bioorg Med Chem (ISSN: 0968-0896, 1464-3391, 0968-0896linking), 2017 Dec 15; 25(24): 6589-6596.
Impact Factor: 2.881
Dettagli Esporta in BibTeX Esporta in EndNote
Berisio R, Squeglia F, Ruggiero A
* Editorial: Molecular Scenarios Behind Infectious Diseases (255 visite)
Curr Med Chem (ISSN: 0929-8673, 1875-533x, 1875-533xelectronic), 2017 Nov 24; 24(36): 3939-3941.
Impact Factor: 3.469
Dettagli Esporta in BibTeX Esporta in EndNote
Leiria Campo V, Riul TB, Oliveira Bortot L, Martins-teixeira MB, Fiori Marchiori M, Iaccarino E, Ruvo M, Dias-baruffi M, Carvalho I
* A Synthetic MUC1 Glycopeptide Bearing betaGalNAc-Thr as a Tn Antigen Isomer Induces the Production of Antibodies against Tumor Cells (782 visite)
Chembiochem (ISSN: 1439-4227, 1439-7633, 1439-4227linking), 2017 Mar 16; 18(6): 527-538.
Impact Factor: 2.774
Dettagli Esporta in BibTeX Esporta in EndNote
Bogdanovich S, Kim Y, Mizutani T, Yasuma R, Tudisco L, Cicatiello V, Bastos-carvalho A, Kerur N, Hirano Y, Baffi JZ, Tarallo V, Li S, Yasuma T, Arpitha P, Fowler BJ, Wright CB, Apicella I, Greco A, Brunetti A, Ruvo M, Sandomenico A, Nozaki M, Ijima R, Kaneko H, Ogura Y, Terasaki H, Ambati BK, Leusen JH, Langdon WY, Clark MR, Armour KL, Bruhns P, Verbeek JS, Gelfand BD, De Falco S, Ambati J
* Human IgG1 antibodies suppress angiogenesis in a target-independent manner (513 visite)
Signal Transduct Target Ther (ISSN: 2059-3635print), 2016; 1: N/D-N/D.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
Strizzi L, Sandomenico A, Margaryan NV, Foca A, Sanguigno L, Bodenstine TM, Chandler GS, Reed DW, Gilgur A, Seftor EA, Seftor RE, Khalkhali-ellis Z, Leonardi A, Ruvo M, Hendrix MJ
* Effects of a novel Nodal-targeting monoclonal antibody in melanoma (356 visite) (PDF 202 visite)
Oncotarget (ISSN: 1949-2553, 1949-2553electronic), 2015 Oct 27; 6(33): 34071-34086.
Impact Factor: 5.008
Dettagli Esporta in BibTeX Esporta in EndNote
Foca A, Sanguigno L, Foca G, Strizzi L, Iannitti R, Palumbo R, Hendrix MJ, Leonardi A, Ruvo M, Sandomenico A
* New Anti-Nodal Monoclonal Antibodies Targeting the Nodal Pre-Helix Loop Involved in Cripto-1 Binding (602 visite) (PDF 248 visite)
Int J Mol Sc (ISSN: 1422-0067, 1661-6596, 1422-0067linking), 2015 Sep 7; 16(9): 21342-21362.
Impact Factor: 3.257
Dettagli Esporta in BibTeX Esporta in EndNote
Calce E, Monfregola L, Saviano M, De Luca S
* HER2-mediated anticancer drug delivery: strategies to prepare targeting ligands highly specific for the receptor (510 visite)
Curr Med Chem (ISSN: 0929-8673, 1875-533x, 1875-533xelectronic), 2015 May 20; 22(21): 2525-2538.
Impact Factor: 3.455
Dettagli Esporta in BibTeX Esporta in EndNote
Cicatiello V, Apicella I, Tudisco L, Tarallo V, Formisano L, Sandomenico A, Kim Y, Bastos-Carvalho A, Orlandi A, Ambati J, Ruvo M, Bianco R, de Falco S
* Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models (354 visite)
Oncotarget (ISSN: 1949-2553, 1949-2553electronic, 1949-2553linking), 2015; 6(12): 10563-10576.
Impact Factor: 5.008
Dettagli Esporta in BibTeX Esporta in EndNote
Gallicchio R, Mansueto G, Simeon V, Nardelli A, Guariglia R, Capacchione D, Soscia E, Pedicini P, Gattozzi D, Musto P, Storto G
* F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma (392 visite)
Eur J Haematol (ISSN: 0902-4441), 2014 May; 92(5): 382-389.
Impact Factor: 2.066
Dettagli Esporta in BibTeX Esporta in EndNote
Dynkevich Y, Rother KI, Whitford I, Qureshi S, Galiveeti S, Szulc AL, Danoff A, Breen TL, Kaviani N, Shanik MH, LeRoith D, Vigneri R, Koch CA, Roth J
* Tumors, IGF-2, and Hypoglycemia: Insights From the Clinic, the Laboratory, and the Historical Archive (1235 visite)
Endocrine Reviews (ISSN: 0163-769x), 2013 Dec; 34(6): 798-826.
Impact Factor: 19.358
Dettagli Esporta in BibTeX Esporta in EndNote
Zhou JS, Sandomenico A, Burton O, Oettgen HC, Ruvo M
* An IgE receptor mimetic peptide (PepE) protects mice from IgE mediated anaphylaxis (384 visite)
Molecular Biosystems (ISSN: 1742-206x), 2013 Nov; 9(11): 2853-2859.
Impact Factor: 3.183
Dettagli Esporta in BibTeX Esporta in EndNote
Mancini M, Greco A, Salvatore G, Liuzzi R, Di Maro G, Vergara E, Chiappetta G, Pasquinelli R, Brunetti A, Salvatore M
* Imaging of thyroid tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice (414 visite)
Bmc Med Imaging (ISSN: 1471-2342, 1471-2342electronic), 2013 Sep 12; 13(1): 31-31.
Impact Factor: 0.983
Dettagli Esporta in BibTeX Esporta in EndNote
Rosa R, Marciano R, Malapelle U, Formisano L, Nappi L, D'Amato C, D'Amato V, Damiano V, Marf G, Del Vecchio S, Zannetti A, Greco A, De Stefano A, Carlomagno C, Veneziani BM, Troncone G, De Placido S, Bianco R
* Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models (503 visite)
Clin Cancer Res (ISSN: 1078-0432, 1078-0432linking, 1078-0432print), 2013 Jan 1; 19(1): 138-147.
Impact Factor: 8.193
Dettagli Esporta in BibTeX Esporta in EndNote
Tagliamonte M, Marasco D, Ruggiero A, de Stradis A, Tornesello ML, Totrov M, Buonaguro FM, Buonaguro L
* HIV p24 as Scaffold for Presenting Conformational HIV Env Antigens (341 visite)
Plosone (ISSN: 1932-6203, 1932-6203electronic), 2012 Sep 17; 7(8): N/D-N/D.
Impact Factor: 3.73
Dettagli Esporta in BibTeX Esporta in EndNote
Pedicini P, Caivano R, Jereczek-Fossa BA, Strigari L, Vischioni B, Alterio D, Cremonesi M, Botta F, Nappi A, Improta G, Storto G, Benassi M, Orecchia R
* Modelling the correlation between EGFr expression and tumour cell radiosensitivity, and combined treatments of radiation and monoclonal antibody EGFr inhibitors (299 visite)
Theor Biol Med Model (ISSN: 1742-4682), 2012 Jun 19; 9(1): 23-23.
Impact Factor: 1.461
Dettagli Esporta in BibTeX Esporta in EndNote
Monti SM, Supuran CT, De Simone G
* Carbonic anhydrase IX as a target for designing novel anticancer drugs (407 visite)
Curr Med Chem (ISSN: 0929-8673, 1875-533x, 1875-533xelectronic), 2012 Feb; 19(6): 821-830.
Impact Factor: 4.07
Dettagli Esporta in BibTeX Esporta in EndNote
Perrone-filardi P, Dellegrottaglie S, Rudd JH, Costanzo P, Marciano C, Vassallo E, Marsico F, Ruggiero D, Petretta MP, Chiariello M, Cuocolo A
* Molecular imaging of atherosclerosis in translational medicine (467 visite)
Eur J Nucl Med (ISSN: 1619-7089, 1619-7070, 0340-6997), 2011 May; 38(5): 969-975.
Impact Factor: 4.991
Dettagli Esporta in BibTeX Esporta in EndNote
Palmieri C, Falcone C, Iaccino E, Tuccillo FM, Gaspari M, Trimboli F, De Laurentiis A, Luberto L, Pontoriero M, Pisano A, Vecchio E, Fierro O, Panico M, Larobina M, Gargiulo S, Costa N, Dal Piaz F, Schiavone M, Arra C, Giudice A, Palma G, Barbieri A, Quinto I, Scala G
* In vivo targeting and growth inhibition of the A20 murine B-cell lymphoma by an idiotype-specific peptide binder (471 visite)
Blood (ISSN: 0006-4971, 0006-6497, 0390-6078), 2010 Jul 15; 116(2): 226-238.
Impact Factor: 10.558
Dettagli Esporta in BibTeX Esporta in EndNote
Napolitano M, Ottaiano A, Mauro F, Ieranò C, Satriano R, Pacelli R, Franco R, De Angelis V, Castello G, Scala S
* CD4(+)CD45RA(+)CXCR4(+) lymphocytes are inversely associated with progression in stages I-III melanoma patients (300 visite)
Cancer Immunol Immunother (ISSN: 0340-7004, 0340-7004linking), 2010 Apr; 59(4): 511-517.
Impact Factor: 4.293
Dettagli Esporta in BibTeX Esporta in EndNote
Alberobello AT, D'Esposito V, Marasco D, Doti N, Ruvo M, Bianco R, Tortora G, Esposito I, Fiory F, Miele C, Beguinot F, Formisano P
* Selective Disruption of Insulin-like Growth Factor-1 (IGF-1) Signaling via Phosphoinositide-dependent Kinase-1 Prevents the Protective Effect of IGF-1 on Human Cancer Cell Death (508 visite)
Jbc Papers (ISSN: 0021-9258, 1083-351x, 0021-9258linking), 2010 Feb 26; 285(9): 6563-6572.
Impact Factor: 5.328
Dettagli Esporta in BibTeX Esporta in EndNote
Storto G, De Renzo A, Pellegrino T, Perna F, De Falco T, Erra P, Nardelli A, Speranza A, Klain M, Rotoli B, Pace L
* Assessment of Metabolic Response to Radioimmunotherapy with (90)Y-Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (336 visite)
Radiology (ISSN: 0033-8419, 1527-1315, 0033-8419linking), 2010 Jan; 254(1): 245-252.
Impact Factor: 6.069
Dettagli Esporta in BibTeX Esporta in EndNote
Mancini M, Greco A, Speranza A, Salvatore M
* Ultrasound molecular imaging by targeted microbubble contrast agents (351 visite)
Minerva Biotecnol (ISSN: 1120-4826), 2009 Jun; 21(2): 97-110.
Impact Factor: 0.268
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Zannetti A, Fonti R, Pace L, Salvatore M
* Nuclear imaging in cancer theranostics (539 visite)
Q J Nucl Med Mol Im (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2007 Jun; 51(2): 152-163.
Impact Factor: 1.724
Dettagli Esporta in BibTeX Esporta in EndNote
Cuocolo A, Milcinski M, Bischof Delaloye A
* Syllabus for postgraduate specialisation in Nuclear Medicine: 2006/07 update (301 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2007 Mar; 34(3): 433-436.
Impact Factor: 4.101
Dettagli Esporta in BibTeX Esporta in EndNote
Palmieri G, Marino M, Salvatore M, Budillon A, Meo G, Caraglia M, Montella L
* Cetuximab is an active treatment of metastatic and chemorefractory thymoma (323 visite)
Frontiers In Bioscience (ISSN: 1093-9946, 1093-4715), 2007 Jan 1; 12(2): 757-761.
Impact Factor: 2.989
Dettagli Esporta in BibTeX Esporta in EndNote
Cuocolo A, Acampa W, Varrone A, Salvatore M
* Highlights of the Annual Congress of the European Association of Nuclear Medicine, Istanbul, 2005: The incremental value of nuclear medicine for patient management and care (467 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2006 Mar; 33(3): 360-381.
Impact Factor: 4.041
Dettagli Esporta in BibTeX Esporta in EndNote
Palumbo R, Capasso D, Brescia F, Mita P, Sarti M, Bersani F, Scarfi MR
* Effects on apoptosis and reactive oxygen species formation by Jurkat cells exposed to 50 Hz electromagnetic fields (500 visite)
Bioelectromagnetics (ISSN: 0197-8462), 2006 Feb; 27(2): 159-162.
Impact Factor: 1.514
Dettagli Esporta in BibTeX Esporta in EndNote
D'Andrea LD, Del Gatto A, Pedone C, Benedetti E
* Peptide-based molecules in angiogenesis (569 visite)
Chem Biol Drug Des (ISSN: 1747-0277, 1747-0285, 1747-0277linking), 2006 Feb; 67(2): 115-126.
Impact Factor: 2.507
Dettagli Esporta in BibTeX Esporta in EndNote
Verdoliva A, Marasco D, De Capua A, Saporito A, Bellofiore P, Manfredi V, Fattorusso R, Pedone C, Ruvo M
* A new ligand for immunoglobulin G subdomains by screening of a synthetic peptide library (420 visite)
Chembiochem (ISSN: 1439-4227, 1439-7633, 1439-7633electronic), 2005 Jul; 6(7): 1242-1253.
Impact Factor: 3.94
Dettagli Esporta in BibTeX Esporta in EndNote
Fonti R, Del Vecchio S, Zannetti A, De Renzo A, Catalano L, Pace L, Rotoli B, Salvatore M
* Functional Imaging Of Multidrug Resistant Phenotype By 99mtc-Mibi Scan In Patients With Multiple Myeloma (421 visite)
Cancer Biotherapy And Radiopharmaceuticals (ISSN: 1084-9785, 1084-4978), 2004; 19(2): 165-170.
Impact Factor: 1.091
Dettagli Esporta in BibTeX Esporta in EndNote
Russo M, Palumbo R, Mupo A, Tosto M, Iacomino G, Scognamiglio A, Tedesco I, Galano G, Russo GL
* Flavonoid quercetin sensitizes a CD95-resistant cell line to apoptosis by activating protein kinase Cα (322 visite)
Oncogene (ISSN: 0950-9232, 1476-5594), 2003; 22(21): 3330-3342.
Impact Factor: 6.495
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Zannetti A, Ciarmiello A, Aloj L, Caracò C, Fonti R, Botti G, D'Aiuto G, Salvatore M
* Dynamic coupling of Tc-99m-MIBI efflux and apoptotic pathway activation in untreated breast cancer patients (414 visite)
Eur J Nucl Med (ISSN: 1619-7070, 0340-6997, 1619-7089), 2002 Jun; 29(6): 809-814.
Impact Factor: 3.568
Dettagli Esporta in BibTeX Esporta in EndNote
Marino M, Rossi M, Ruvo M, Fassina G
* Novel molecular targets for systemic lupus erythematosus (328 visite)
Curr Drug Targets (ISSN: 1389-4501), 2002 Jun; 3(3): 223-228.
Impact Factor: 3.597
Dettagli Esporta in BibTeX Esporta in EndNote
Russo M, Palumbo R, Tedesco I, Mazzarella G, Russo P, Iacomino G, Russo GL
Quercetin and anti-CD95(Fas/Apo1) enhance apoptosis in HPB-ALL cell line (333 visite)
Febs Lett (ISSN: 0014-5793, 0014-5793print, 1873-3468electronic), 1999 Dec 3; 462(3): 322-328.
Impact Factor: 3.72
Dettagli Esporta in BibTeX Esporta in EndNote
Fonti R, Levchenko A, Mehta BM, Zhang J, Tsuruo T, Larson SM
Measurement of P-glycoprotein expression in human neuroblastoma xenografts using in vitro quantitative autoradiography (231 visite)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897), 1999 Jan; 26(1): 35-41.
Impact Factor: 1.623
Dettagli Esporta in BibTeX Esporta in EndNote
Fonti R, Cheung N-KV, Bridger GJ, Guo H-F, Abrams MJ, Larson SM
99mTc-monoclonal antibody radiolabeled via hydrazino nicotinamide derivative for imaging disialoganglioside G(D2)-positive tumors (289 visite)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897), 1999; 26(6): 681-686.
Impact Factor: 1.623
Dettagli Esporta in BibTeX Esporta in EndNote
Fonti R, Cheung NKV, Bridger GJ, Shen SQ, Finn RD, Abrams RJ, Larson SM
Technetium-99m-Monoclonal Antibody Radio-Labeled Via Hydrazino Nicotinamide Derivative For Imaging Ganglioside Gd2-Positive Tumors (225 visite)
Nucl Med Biol, 1999; 26: 681-686.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
Renda A, Iovino F, Capasso L, Ricciardelli L, Tammaro V, Acampa W
Radioimmunoguided surgery in colorectal cancer: A 6-year experience with four different technical solutions (238 visite)
Semin Surg Oncol Wiley Liss Inc (ISSN: 8756-0437), 1998 Dec; 15(4): 226-230.
Impact Factor: 1.045
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Ciarmiello A, Pace L, Potena MI, Carriero MV, Mainolfi C, Thomas R, D'Aiuto G, Tsuruo T, Salvatore M
Fractional retention of technetium-99m-sestamibi as an index of P- glycoprotein expression in untreated breast cancer patients (420 visite)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1997 Sep; 38(9): 1348-1351.
Impact Factor: 3.491
Dettagli Esporta in BibTeX Esporta in EndNote
Vecchio SD, Ciarmiello A, Potena MI, Carriero MV, Mainolfi C, Botti G, Thomas R, Cerra M, D'Aiuto G, Tsuruo T, Salvatore M
In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients (273 visite)
Eur J Nucl Med (ISSN: 0340-6997print, 0340-6997linking), 1997 Feb; 24(2): 150-159.
Impact Factor: 5.036
Dettagli Esporta in BibTeX Esporta in EndNote
Levchenko A, Mehta B, Spengler BA, Narkar A, Fonti R, Biedler JL, Tsuruo T, Larson SM
Measurement of P-glycoprotein expression in multidrug-resistant human neuroblastoma cell lines using self-competitive binding assay (232 visite)
Anal Biochem (ISSN: 0003-2697, 1096-0309electronic), 1996 May 1; 236(2): 338-343.
Impact Factor: 2.017
Dettagli Esporta in BibTeX Esporta in EndNote
Li PY, Del Vecchio S, Fonti R, Carriero MV, Potena MI, Botti G, Miotti S, Lastoria S, Menard S, Colnaghi MI, Salvatore M
Local concentration of folate binding protein GP38 in sections of human ovarian carcinoma by in vitro quantitative autoradiography (397 visite)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1996 Apr; 37(4-6): 665-672.
Impact Factor: 3.491
Dettagli Esporta in BibTeX Esporta in EndNote
Latella G, Fonti R, Caprilli R, Marcheggiano A, Magliocca F, Das KM, Gambús G, Sambuy Y
Characterization of the mucins produced by normal human colonocytes in primary culture (237 visite)
International Journal Of Colorectal Disease (ISSN: 0179-1958, 0179-1958linking), 1996; 11(2): 76-83.
Impact Factor: 0.732
Dettagli Esporta in BibTeX Esporta in EndNote
Carriero MV, Franco P, Del Vecchio S, Massa O, Botti G, D'Aiuto G, Stoppelli MP, Salvatore M
Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies (386 visite)
Cancer Res (ISSN: 0008-5472, 1538-7445, 1538-7445electronic), 1994 Oct 15; 54(20): 5445-5454.
Impact Factor: 8.426
Dettagli Esporta in BibTeX Esporta in EndNote
Caraglia M, Tagliaferri P, Correale P, Genua G, Pinto A, Del Vecchio S, Esposito G, Bianco AR
CYTOSINE-ARABINOSIDE INCREASES THE BINDING OF I-125 LABELED EPIDERMAL GROWTH-FACTOR AND I-125 TRANSFERRIN AND ENHANCES THE IN-VITRO TARGETING OF HUMAN TUMOR-CELLS WITH ANTI-(GROWTH FACTOR-RECEPTOR) MAB (274 visite)
Cancer Immunol Immunother (ISSN: 0340-7004, 0340-7004linking), 1993 Sep; 37(3): 150-156.
Impact Factor: 1.269
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Stoppelli MP, Carriere MV, Fonti R, Massa O, Li PY, Botti G, Cerra M, D'Aiuto G, Esposito G, Salvatore M
Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: Comparison with urokinase levels (227 visite)
Cancer Res (ISSN: 0008-5472, 1538-7445, 1538-7445electronic), 1993 Jul 1; 53(13): 3198-3206.
Impact Factor: 8.426
Dettagli Esporta in BibTeX Esporta in EndNote
Sofia M, Del Vecchio S, Petrillo A, Mormile M, Salvatore M, Carratù L
Endobronchial deposition of radioactive monoclonal antibody in patients with inoperable non-small-cell carcinoma of the lung [4] (243 visite)
Chest (ISSN: 0012-3692), 1992 Nov; 102(5): 1632-1634.
Impact Factor: 2.341
Dettagli Esporta in BibTeX Esporta in EndNote
D'Aiuto G, Del Vecchio S, Mansi L, D'Aprile M, Botti G, Salvatore M
Malignant melanoma of the nipple: A case studied with radiolabeled monoclonal antibody (539 visite)
Tumori (ISSN: 0300-8916, 0300-8916print, 0300-8916linking), 1991 Oct 31; 77(5): 449-451.
Impact Factor: 0.408
Dettagli Esporta in BibTeX Esporta in EndNote
Scala S, Pacelli R, Iaffaioli RV, Normanno N, Pepe S, Frasci G, Genua G, Tsuruo T, Tagliaferri P, Bianco AR
Reversal of adriamycin resistance by recombinant α-interferon in multidrug-resistant human colon carcinoma LoVo-doxorubicin cells (495 visite)
Cancer Res (ISSN: 0008-5472, 1538-7445, 1538-7445electronic), 1991 Sep 15; 51(18): 4898-4902.
Impact Factor: 8.426
Dettagli Esporta in BibTeX Esporta in EndNote
Camera L, Del Vecchio S, Petrillo A, Esposito G, Frasci G, Iaffaioli RV, Bianco AR, Salvatore M
Evaluation of therapeutic response using iodine-131-B72. 3 monoclonal antibody in patients with ovarian carcinoma (402 visite)
Eur J Nucl Med (ISSN: 0340-6997, 1619-7070, 1619-7089), 1991 Apr; 18(4): 269-273.
Impact Factor: 2.692
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Camera L, Petrillo A, Esposito G, Frasci G, Iaffaioli RV, Bianco AR, Salvatore M
Clinical studies with B72. 3 in ovarian cancer and probe-guided tumor localization (345 visite)
Nucl Med Biol (ISSN: 0883-2897, 0969-8051), 1991; 18(1): 85-87.
Impact Factor: 1.042
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Mansi L, Petrillo A, Camera L, Sofia M, Marra A, Carratú L, Salvatore M
Endobronchial administration of iodine-131 B72. 3 monoclonal antibody in patients with lung cancer (239 visite)
Eur J Nucl Med (ISSN: 0340-6997, 1619-7070, 1619-7089), 1991; 18(2): 129-132.
Impact Factor: 2.692
Dettagli Esporta in BibTeX Esporta in EndNote
Valenza V, Maussier ML, D'Errico G, Lemmo GF, Frontera D, Ferrante A, Saletnich I, Valli A, Quarantelli M
Cancer of the pancreas and the periampullary region: The usefulness of tumor marker products with the monoclonal antibody technique (241 visite)
J Nucl Med Allied Sci (ISSN: 0392-0208), 1990 Oct; 34(4SUPPL.): 131-134.
Impact Factor: 1.91
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Reynolds JC
NONUNIFORM DISTRIBUTION OF RADIOLABELED MONOCLONAL-ANTIBODY IN TUMOR (218 visite)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1990 Jul; 31(7): 1252-1252.
Impact Factor: 3.491
Dettagli Esporta in BibTeX Esporta in EndNote
Pezzino V, Papa V, Trischitta V, Brunetti A, Goodman PA, Treutelaar MK, Williams JA, Maddux BA, Vigneri R, Goldfine ID
Human insulin receptor radioimmunoassay: Applicability to insulin-resistant states (216 visite)
Am J Physiol Endocrinol Metab (ISSN: 0002-9513), 1989 Sep; 257(3): N/D-N/D.
Impact Factor: 3.116
Dettagli Esporta in BibTeX Esporta in EndNote
Trischitta V, Wong KY, Brunetti A, Scalisi R, Vigneri R, Goldfine ID
Endocytosis, recycling, and degradation of the insulin receptor. Studies with monoclonal antireceptor antibodies that do not activate receptor kinase (287 visite)
Jbc Papers (ISSN: 0021-9258, 1083-351x, 0021-9258linking), 1989 Mar 25; 264(9): 5041-5046.
Impact Factor: 6.963
Dettagli Esporta in BibTeX Esporta in EndNote
d'Onofrio G, Menichella G, Zini G, Rumi C, Pierelli L, Quarantelli M, Puggioni PL, Mango G
Lymphocyte subset counting by immunoperoxidase using an automated routine hematologic analyzer (334 visite)
Haematologica (ISSN: 0390-6078, 0006-4971, 0006-6497), 1989 Mar; 74(2): 137-142.
Impact Factor: 2.56
Dettagli Esporta in BibTeX Esporta in EndNote
Reynolds JC, Del Vecchio S, Sakahara H, Lora ME, Carrasquillo JA, Neumann RD, Larson SM
ANTI-MURINE ANTIBODY RESPONSE TO MOUSE MONOCLONAL ANTIBODIES CLINICAL FINDINGS AND IMPLICATIONS (501 visite)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897), 1989; 16(2): 121-125.
Impact Factor: 1.042
Dettagli Esporta in BibTeX Esporta in EndNote
Salvatore M, Lastoria S, Del Vecchio S, Mansi L
Detection of colon cancer with radiolabelled monoclonal antibodies (267 visite)
Nucl Med Biol (ISSN: 0883-2897, 0969-8051), 1989; 16(2): 103-104.
Impact Factor: 1.042
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Reynolds JC
DETERMINATION OF ANTIGEN CONCENTRATION AND DISTRIBUTION IN HUMAN TUMORS THE QUANTITATIVE AUTORADIOGRAPHIC APPROACH (259 visite)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897), 1989; 16(2): 143-145.
Impact Factor: 1.042
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Reynolds JC, Carrasquillo JA, Blasberg RG, Neumann RD, Lotze MT, Bryant GJ, Farkas RJ, Larson SM
Local distribution and concentration of intravenously injected 131I-9. 2. 27 monoclonal antibody in human malignant melanoma (275 visite)
Cancer Res (ISSN: 0008-5472, 1538-7445, 1538-7445electronic), 1989; 49(10): 2783-2789.
Impact Factor: 8.426
Dettagli Esporta in BibTeX Esporta in EndNote
DEL VECCHIO S, MANSI L, GAGLIARDI N, PETRILLO A, SOFIA M, CARRATU L, SALVATORE M
INTRABRONCHIAL ADMINISTRATION OF IODINE-131 B72. 3 MONOCLONAL ANTIBODY IN PATIENTS WITH LUNG CANCER (254 visite)
Eur J Nucl Med (ISSN: 0340-6997, 1619-7070, 1619-7089), 1988; 14(5-6): N/D-N/D.
Impact Factor: 2.692
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Reynolds JC, Blasberg RG, Neumann RD, Carrasquillo JA, Hellström I, Larson SM
Measurement of local Mr 97, 000 and 250, 000 protein antigen concentration in sections of human melanoma tumor using in vitro quantitative autoradiography (449 visite)
Cancer Res (ISSN: 0008-5472, 1538-7445, 1538-7445electronic), 1988; 48(19): 5475-5481.
Impact Factor: 8.426
Dettagli Esporta in BibTeX Esporta in EndNote
Search related bibliography on PubMed Cerca bibliografia collegata su PubMed
Vai a fine pagina Versione per copia e incolla facile Esporta tutto in BibTeX Esporta tutto in EndNote
Camorani S, Passariello M, Agnello L, Esposito S, Collina F, Cantile M, Di Bonito M, Ulasov IV, Fedele M, Zannetti A, De Lorenzo C, Cerchia L
* Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer (68 visite) (PDF 37 visite)
J Exp Clin Cancer Res (ISSN: 0392-9078linking), 2020 Sep 7; 39(1): 180-180.
Impact Factor: 7.068
Dettagli Esporta in BibTeX Esporta in EndNote
Sandomenico A, Sivaccumar JP, Ruvo M
* Evolution of Escherichia coli Expression System in Producing Antibody Recombinant Fragments (36 visite)
Int J Mol Sci (ISSN: 1422-0067linking), 2020 Aug 31; 21(17): N/D-N/D.
Impact Factor: 4.556
Dettagli Esporta in BibTeX Esporta in EndNote
Bertani L, Caviglia GP, Antonioli L, Pellicano R, Fagoonee S, Astegiano M, Saracco GM, Bugianesi E, Blandizzi C, Costa F, Ribaldone DG
* Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases (84 visite)
J Clin Med (ISSN: 2077-0383electronic, 2077-0383linking), 2020 May 2; 9(5): N/D-N/D.
Impact Factor: 6.78
Dettagli Esporta in BibTeX Esporta in EndNote
Sivaccumar J, Sandomenico A, Vitagliano L, Ruvo M
* Monoclonal antibodies: A prospective and retrospective view (33 visite)
Curr Med Chem (ISSN: 0929-8673linking), 2020 Feb 19; N/D: N/D-N/D.
Impact Factor: 4.184
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, Kellner M, Esposito D, Liesche-starnecker F, Bua S, Supuran CT, Monti SM, Zeidler R, De Simone G
* Biochemical and structural insights into Carbonic Anhydrase XII/Fab6A10 complex (133 visite)
J Mol Biol (ISSN: 0022-2836linking, 1089-8638), 2019 Dec 6; 431(24): 4910-4921.
Impact Factor: 5.067
Dettagli Esporta in BibTeX Esporta in EndNote
Supuran CT, Alterio V, Di Fiore A, D'Ambrosio K, Carta F, Monti SM, De Simone G
* Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: Three for the price of one (250 visite)
Med Res Rev (ISSN: 1098-1128electronic, 0198-6325linking), 2018 Sep; 38(6): 1799-1836.
Impact Factor: 8.29
Dettagli Esporta in BibTeX Esporta in EndNote
Calvanese L, Foca A, Sandomenico A, Foca G, Caporale A, Doti N, Iaccarino E, Leonardi A, D'Auria G, Ruvo M, Falcigno L
* Structural insights into the interaction of a monoclonal antibody and Nodal peptides by STD-NMR spectroscopy (453 visite)
Bioorg Med Chem (ISSN: 0968-0896, 1464-3391, 0968-0896linking), 2017 Dec 15; 25(24): 6589-6596.
Impact Factor: 2.881
Dettagli Esporta in BibTeX Esporta in EndNote
Berisio R, Squeglia F, Ruggiero A
* Editorial: Molecular Scenarios Behind Infectious Diseases (255 visite)
Curr Med Chem (ISSN: 0929-8673, 1875-533x, 1875-533xelectronic), 2017 Nov 24; 24(36): 3939-3941.
Impact Factor: 3.469
Dettagli Esporta in BibTeX Esporta in EndNote
Leiria Campo V, Riul TB, Oliveira Bortot L, Martins-teixeira MB, Fiori Marchiori M, Iaccarino E, Ruvo M, Dias-baruffi M, Carvalho I
* A Synthetic MUC1 Glycopeptide Bearing betaGalNAc-Thr as a Tn Antigen Isomer Induces the Production of Antibodies against Tumor Cells (782 visite)
Chembiochem (ISSN: 1439-4227, 1439-7633, 1439-4227linking), 2017 Mar 16; 18(6): 527-538.
Impact Factor: 2.774
Dettagli Esporta in BibTeX Esporta in EndNote
Bogdanovich S, Kim Y, Mizutani T, Yasuma R, Tudisco L, Cicatiello V, Bastos-carvalho A, Kerur N, Hirano Y, Baffi JZ, Tarallo V, Li S, Yasuma T, Arpitha P, Fowler BJ, Wright CB, Apicella I, Greco A, Brunetti A, Ruvo M, Sandomenico A, Nozaki M, Ijima R, Kaneko H, Ogura Y, Terasaki H, Ambati BK, Leusen JH, Langdon WY, Clark MR, Armour KL, Bruhns P, Verbeek JS, Gelfand BD, De Falco S, Ambati J
* Human IgG1 antibodies suppress angiogenesis in a target-independent manner (513 visite)
Signal Transduct Target Ther (ISSN: 2059-3635print), 2016; 1: N/D-N/D.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
Strizzi L, Sandomenico A, Margaryan NV, Foca A, Sanguigno L, Bodenstine TM, Chandler GS, Reed DW, Gilgur A, Seftor EA, Seftor RE, Khalkhali-ellis Z, Leonardi A, Ruvo M, Hendrix MJ
* Effects of a novel Nodal-targeting monoclonal antibody in melanoma (356 visite) (PDF 202 visite)
Oncotarget (ISSN: 1949-2553, 1949-2553electronic), 2015 Oct 27; 6(33): 34071-34086.
Impact Factor: 5.008
Dettagli Esporta in BibTeX Esporta in EndNote
Foca A, Sanguigno L, Foca G, Strizzi L, Iannitti R, Palumbo R, Hendrix MJ, Leonardi A, Ruvo M, Sandomenico A
* New Anti-Nodal Monoclonal Antibodies Targeting the Nodal Pre-Helix Loop Involved in Cripto-1 Binding (602 visite) (PDF 248 visite)
Int J Mol Sc (ISSN: 1422-0067, 1661-6596, 1422-0067linking), 2015 Sep 7; 16(9): 21342-21362.
Impact Factor: 3.257
Dettagli Esporta in BibTeX Esporta in EndNote
Calce E, Monfregola L, Saviano M, De Luca S
* HER2-mediated anticancer drug delivery: strategies to prepare targeting ligands highly specific for the receptor (510 visite)
Curr Med Chem (ISSN: 0929-8673, 1875-533x, 1875-533xelectronic), 2015 May 20; 22(21): 2525-2538.
Impact Factor: 3.455
Dettagli Esporta in BibTeX Esporta in EndNote
Cicatiello V, Apicella I, Tudisco L, Tarallo V, Formisano L, Sandomenico A, Kim Y, Bastos-Carvalho A, Orlandi A, Ambati J, Ruvo M, Bianco R, de Falco S
* Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models (354 visite)
Oncotarget (ISSN: 1949-2553, 1949-2553electronic, 1949-2553linking), 2015; 6(12): 10563-10576.
Impact Factor: 5.008
Dettagli Esporta in BibTeX Esporta in EndNote
Gallicchio R, Mansueto G, Simeon V, Nardelli A, Guariglia R, Capacchione D, Soscia E, Pedicini P, Gattozzi D, Musto P, Storto G
* F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma (392 visite)
Eur J Haematol (ISSN: 0902-4441), 2014 May; 92(5): 382-389.
Impact Factor: 2.066
Dettagli Esporta in BibTeX Esporta in EndNote
Dynkevich Y, Rother KI, Whitford I, Qureshi S, Galiveeti S, Szulc AL, Danoff A, Breen TL, Kaviani N, Shanik MH, LeRoith D, Vigneri R, Koch CA, Roth J
* Tumors, IGF-2, and Hypoglycemia: Insights From the Clinic, the Laboratory, and the Historical Archive (1235 visite)
Endocrine Reviews (ISSN: 0163-769x), 2013 Dec; 34(6): 798-826.
Impact Factor: 19.358
Dettagli Esporta in BibTeX Esporta in EndNote
Zhou JS, Sandomenico A, Burton O, Oettgen HC, Ruvo M
* An IgE receptor mimetic peptide (PepE) protects mice from IgE mediated anaphylaxis (384 visite)
Molecular Biosystems (ISSN: 1742-206x), 2013 Nov; 9(11): 2853-2859.
Impact Factor: 3.183
Dettagli Esporta in BibTeX Esporta in EndNote
Mancini M, Greco A, Salvatore G, Liuzzi R, Di Maro G, Vergara E, Chiappetta G, Pasquinelli R, Brunetti A, Salvatore M
* Imaging of thyroid tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice (414 visite)
Bmc Med Imaging (ISSN: 1471-2342, 1471-2342electronic), 2013 Sep 12; 13(1): 31-31.
Impact Factor: 0.983
Dettagli Esporta in BibTeX Esporta in EndNote
Rosa R, Marciano R, Malapelle U, Formisano L, Nappi L, D'Amato C, D'Amato V, Damiano V, Marf G, Del Vecchio S, Zannetti A, Greco A, De Stefano A, Carlomagno C, Veneziani BM, Troncone G, De Placido S, Bianco R
* Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models (503 visite)
Clin Cancer Res (ISSN: 1078-0432, 1078-0432linking, 1078-0432print), 2013 Jan 1; 19(1): 138-147.
Impact Factor: 8.193
Dettagli Esporta in BibTeX Esporta in EndNote
Tagliamonte M, Marasco D, Ruggiero A, de Stradis A, Tornesello ML, Totrov M, Buonaguro FM, Buonaguro L
* HIV p24 as Scaffold for Presenting Conformational HIV Env Antigens (341 visite)
Plosone (ISSN: 1932-6203, 1932-6203electronic), 2012 Sep 17; 7(8): N/D-N/D.
Impact Factor: 3.73
Dettagli Esporta in BibTeX Esporta in EndNote
Pedicini P, Caivano R, Jereczek-Fossa BA, Strigari L, Vischioni B, Alterio D, Cremonesi M, Botta F, Nappi A, Improta G, Storto G, Benassi M, Orecchia R
* Modelling the correlation between EGFr expression and tumour cell radiosensitivity, and combined treatments of radiation and monoclonal antibody EGFr inhibitors (299 visite)
Theor Biol Med Model (ISSN: 1742-4682), 2012 Jun 19; 9(1): 23-23.
Impact Factor: 1.461
Dettagli Esporta in BibTeX Esporta in EndNote
Monti SM, Supuran CT, De Simone G
* Carbonic anhydrase IX as a target for designing novel anticancer drugs (407 visite)
Curr Med Chem (ISSN: 0929-8673, 1875-533x, 1875-533xelectronic), 2012 Feb; 19(6): 821-830.
Impact Factor: 4.07
Dettagli Esporta in BibTeX Esporta in EndNote
Perrone-filardi P, Dellegrottaglie S, Rudd JH, Costanzo P, Marciano C, Vassallo E, Marsico F, Ruggiero D, Petretta MP, Chiariello M, Cuocolo A
* Molecular imaging of atherosclerosis in translational medicine (467 visite)
Eur J Nucl Med (ISSN: 1619-7089, 1619-7070, 0340-6997), 2011 May; 38(5): 969-975.
Impact Factor: 4.991
Dettagli Esporta in BibTeX Esporta in EndNote
Palmieri C, Falcone C, Iaccino E, Tuccillo FM, Gaspari M, Trimboli F, De Laurentiis A, Luberto L, Pontoriero M, Pisano A, Vecchio E, Fierro O, Panico M, Larobina M, Gargiulo S, Costa N, Dal Piaz F, Schiavone M, Arra C, Giudice A, Palma G, Barbieri A, Quinto I, Scala G
* In vivo targeting and growth inhibition of the A20 murine B-cell lymphoma by an idiotype-specific peptide binder (471 visite)
Blood (ISSN: 0006-4971, 0006-6497, 0390-6078), 2010 Jul 15; 116(2): 226-238.
Impact Factor: 10.558
Dettagli Esporta in BibTeX Esporta in EndNote
Napolitano M, Ottaiano A, Mauro F, Ieranò C, Satriano R, Pacelli R, Franco R, De Angelis V, Castello G, Scala S
* CD4(+)CD45RA(+)CXCR4(+) lymphocytes are inversely associated with progression in stages I-III melanoma patients (300 visite)
Cancer Immunol Immunother (ISSN: 0340-7004, 0340-7004linking), 2010 Apr; 59(4): 511-517.
Impact Factor: 4.293
Dettagli Esporta in BibTeX Esporta in EndNote
Alberobello AT, D'Esposito V, Marasco D, Doti N, Ruvo M, Bianco R, Tortora G, Esposito I, Fiory F, Miele C, Beguinot F, Formisano P
* Selective Disruption of Insulin-like Growth Factor-1 (IGF-1) Signaling via Phosphoinositide-dependent Kinase-1 Prevents the Protective Effect of IGF-1 on Human Cancer Cell Death (508 visite)
Jbc Papers (ISSN: 0021-9258, 1083-351x, 0021-9258linking), 2010 Feb 26; 285(9): 6563-6572.
Impact Factor: 5.328
Dettagli Esporta in BibTeX Esporta in EndNote
Storto G, De Renzo A, Pellegrino T, Perna F, De Falco T, Erra P, Nardelli A, Speranza A, Klain M, Rotoli B, Pace L
* Assessment of Metabolic Response to Radioimmunotherapy with (90)Y-Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (336 visite)
Radiology (ISSN: 0033-8419, 1527-1315, 0033-8419linking), 2010 Jan; 254(1): 245-252.
Impact Factor: 6.069
Dettagli Esporta in BibTeX Esporta in EndNote
Mancini M, Greco A, Speranza A, Salvatore M
* Ultrasound molecular imaging by targeted microbubble contrast agents (351 visite)
Minerva Biotecnol (ISSN: 1120-4826), 2009 Jun; 21(2): 97-110.
Impact Factor: 0.268
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Zannetti A, Fonti R, Pace L, Salvatore M
* Nuclear imaging in cancer theranostics (539 visite)
Q J Nucl Med Mol Im (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2007 Jun; 51(2): 152-163.
Impact Factor: 1.724
Dettagli Esporta in BibTeX Esporta in EndNote
Cuocolo A, Milcinski M, Bischof Delaloye A
* Syllabus for postgraduate specialisation in Nuclear Medicine: 2006/07 update (301 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2007 Mar; 34(3): 433-436.
Impact Factor: 4.101
Dettagli Esporta in BibTeX Esporta in EndNote
Palmieri G, Marino M, Salvatore M, Budillon A, Meo G, Caraglia M, Montella L
* Cetuximab is an active treatment of metastatic and chemorefractory thymoma (323 visite)
Frontiers In Bioscience (ISSN: 1093-9946, 1093-4715), 2007 Jan 1; 12(2): 757-761.
Impact Factor: 2.989
Dettagli Esporta in BibTeX Esporta in EndNote
Cuocolo A, Acampa W, Varrone A, Salvatore M
* Highlights of the Annual Congress of the European Association of Nuclear Medicine, Istanbul, 2005: The incremental value of nuclear medicine for patient management and care (467 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2006 Mar; 33(3): 360-381.
Impact Factor: 4.041
Dettagli Esporta in BibTeX Esporta in EndNote
Palumbo R, Capasso D, Brescia F, Mita P, Sarti M, Bersani F, Scarfi MR
* Effects on apoptosis and reactive oxygen species formation by Jurkat cells exposed to 50 Hz electromagnetic fields (500 visite)
Bioelectromagnetics (ISSN: 0197-8462), 2006 Feb; 27(2): 159-162.
Impact Factor: 1.514
Dettagli Esporta in BibTeX Esporta in EndNote
D'Andrea LD, Del Gatto A, Pedone C, Benedetti E
* Peptide-based molecules in angiogenesis (569 visite)
Chem Biol Drug Des (ISSN: 1747-0277, 1747-0285, 1747-0277linking), 2006 Feb; 67(2): 115-126.
Impact Factor: 2.507
Dettagli Esporta in BibTeX Esporta in EndNote
Verdoliva A, Marasco D, De Capua A, Saporito A, Bellofiore P, Manfredi V, Fattorusso R, Pedone C, Ruvo M
* A new ligand for immunoglobulin G subdomains by screening of a synthetic peptide library (420 visite)
Chembiochem (ISSN: 1439-4227, 1439-7633, 1439-7633electronic), 2005 Jul; 6(7): 1242-1253.
Impact Factor: 3.94
Dettagli Esporta in BibTeX Esporta in EndNote
Fonti R, Del Vecchio S, Zannetti A, De Renzo A, Catalano L, Pace L, Rotoli B, Salvatore M
* Functional Imaging Of Multidrug Resistant Phenotype By 99mtc-Mibi Scan In Patients With Multiple Myeloma (421 visite)
Cancer Biotherapy And Radiopharmaceuticals (ISSN: 1084-9785, 1084-4978), 2004; 19(2): 165-170.
Impact Factor: 1.091
Dettagli Esporta in BibTeX Esporta in EndNote
Russo M, Palumbo R, Mupo A, Tosto M, Iacomino G, Scognamiglio A, Tedesco I, Galano G, Russo GL
* Flavonoid quercetin sensitizes a CD95-resistant cell line to apoptosis by activating protein kinase Cα (322 visite)
Oncogene (ISSN: 0950-9232, 1476-5594), 2003; 22(21): 3330-3342.
Impact Factor: 6.495
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Zannetti A, Ciarmiello A, Aloj L, Caracò C, Fonti R, Botti G, D'Aiuto G, Salvatore M
* Dynamic coupling of Tc-99m-MIBI efflux and apoptotic pathway activation in untreated breast cancer patients (414 visite)
Eur J Nucl Med (ISSN: 1619-7070, 0340-6997, 1619-7089), 2002 Jun; 29(6): 809-814.
Impact Factor: 3.568
Dettagli Esporta in BibTeX Esporta in EndNote
Marino M, Rossi M, Ruvo M, Fassina G
* Novel molecular targets for systemic lupus erythematosus (328 visite)
Curr Drug Targets (ISSN: 1389-4501), 2002 Jun; 3(3): 223-228.
Impact Factor: 3.597
Dettagli Esporta in BibTeX Esporta in EndNote
Russo M, Palumbo R, Tedesco I, Mazzarella G, Russo P, Iacomino G, Russo GL
Quercetin and anti-CD95(Fas/Apo1) enhance apoptosis in HPB-ALL cell line (333 visite)
Febs Lett (ISSN: 0014-5793, 0014-5793print, 1873-3468electronic), 1999 Dec 3; 462(3): 322-328.
Impact Factor: 3.72
Dettagli Esporta in BibTeX Esporta in EndNote
Fonti R, Levchenko A, Mehta BM, Zhang J, Tsuruo T, Larson SM
Measurement of P-glycoprotein expression in human neuroblastoma xenografts using in vitro quantitative autoradiography (231 visite)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897), 1999 Jan; 26(1): 35-41.
Impact Factor: 1.623
Dettagli Esporta in BibTeX Esporta in EndNote
Fonti R, Cheung N-KV, Bridger GJ, Guo H-F, Abrams MJ, Larson SM
99mTc-monoclonal antibody radiolabeled via hydrazino nicotinamide derivative for imaging disialoganglioside G(D2)-positive tumors (289 visite)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897), 1999; 26(6): 681-686.
Impact Factor: 1.623
Dettagli Esporta in BibTeX Esporta in EndNote
Fonti R, Cheung NKV, Bridger GJ, Shen SQ, Finn RD, Abrams RJ, Larson SM
Technetium-99m-Monoclonal Antibody Radio-Labeled Via Hydrazino Nicotinamide Derivative For Imaging Ganglioside Gd2-Positive Tumors (225 visite)
Nucl Med Biol, 1999; 26: 681-686.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
Renda A, Iovino F, Capasso L, Ricciardelli L, Tammaro V, Acampa W
Radioimmunoguided surgery in colorectal cancer: A 6-year experience with four different technical solutions (238 visite)
Semin Surg Oncol Wiley Liss Inc (ISSN: 8756-0437), 1998 Dec; 15(4): 226-230.
Impact Factor: 1.045
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Ciarmiello A, Pace L, Potena MI, Carriero MV, Mainolfi C, Thomas R, D'Aiuto G, Tsuruo T, Salvatore M
Fractional retention of technetium-99m-sestamibi as an index of P- glycoprotein expression in untreated breast cancer patients (420 visite)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1997 Sep; 38(9): 1348-1351.
Impact Factor: 3.491
Dettagli Esporta in BibTeX Esporta in EndNote
Vecchio SD, Ciarmiello A, Potena MI, Carriero MV, Mainolfi C, Botti G, Thomas R, Cerra M, D'Aiuto G, Tsuruo T, Salvatore M
In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients (273 visite)
Eur J Nucl Med (ISSN: 0340-6997print, 0340-6997linking), 1997 Feb; 24(2): 150-159.
Impact Factor: 5.036
Dettagli Esporta in BibTeX Esporta in EndNote
Levchenko A, Mehta B, Spengler BA, Narkar A, Fonti R, Biedler JL, Tsuruo T, Larson SM
Measurement of P-glycoprotein expression in multidrug-resistant human neuroblastoma cell lines using self-competitive binding assay (232 visite)
Anal Biochem (ISSN: 0003-2697, 1096-0309electronic), 1996 May 1; 236(2): 338-343.
Impact Factor: 2.017
Dettagli Esporta in BibTeX Esporta in EndNote
Li PY, Del Vecchio S, Fonti R, Carriero MV, Potena MI, Botti G, Miotti S, Lastoria S, Menard S, Colnaghi MI, Salvatore M
Local concentration of folate binding protein GP38 in sections of human ovarian carcinoma by in vitro quantitative autoradiography (397 visite)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1996 Apr; 37(4-6): 665-672.
Impact Factor: 3.491
Dettagli Esporta in BibTeX Esporta in EndNote
Latella G, Fonti R, Caprilli R, Marcheggiano A, Magliocca F, Das KM, Gambús G, Sambuy Y
Characterization of the mucins produced by normal human colonocytes in primary culture (237 visite)
International Journal Of Colorectal Disease (ISSN: 0179-1958, 0179-1958linking), 1996; 11(2): 76-83.
Impact Factor: 0.732
Dettagli Esporta in BibTeX Esporta in EndNote
Carriero MV, Franco P, Del Vecchio S, Massa O, Botti G, D'Aiuto G, Stoppelli MP, Salvatore M
Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies (386 visite)
Cancer Res (ISSN: 0008-5472, 1538-7445, 1538-7445electronic), 1994 Oct 15; 54(20): 5445-5454.
Impact Factor: 8.426
Dettagli Esporta in BibTeX Esporta in EndNote
Caraglia M, Tagliaferri P, Correale P, Genua G, Pinto A, Del Vecchio S, Esposito G, Bianco AR
CYTOSINE-ARABINOSIDE INCREASES THE BINDING OF I-125 LABELED EPIDERMAL GROWTH-FACTOR AND I-125 TRANSFERRIN AND ENHANCES THE IN-VITRO TARGETING OF HUMAN TUMOR-CELLS WITH ANTI-(GROWTH FACTOR-RECEPTOR) MAB (274 visite)
Cancer Immunol Immunother (ISSN: 0340-7004, 0340-7004linking), 1993 Sep; 37(3): 150-156.
Impact Factor: 1.269
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Stoppelli MP, Carriere MV, Fonti R, Massa O, Li PY, Botti G, Cerra M, D'Aiuto G, Esposito G, Salvatore M
Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: Comparison with urokinase levels (227 visite)
Cancer Res (ISSN: 0008-5472, 1538-7445, 1538-7445electronic), 1993 Jul 1; 53(13): 3198-3206.
Impact Factor: 8.426
Dettagli Esporta in BibTeX Esporta in EndNote
Sofia M, Del Vecchio S, Petrillo A, Mormile M, Salvatore M, Carratù L
Endobronchial deposition of radioactive monoclonal antibody in patients with inoperable non-small-cell carcinoma of the lung [4] (243 visite)
Chest (ISSN: 0012-3692), 1992 Nov; 102(5): 1632-1634.
Impact Factor: 2.341
Dettagli Esporta in BibTeX Esporta in EndNote
D'Aiuto G, Del Vecchio S, Mansi L, D'Aprile M, Botti G, Salvatore M
Malignant melanoma of the nipple: A case studied with radiolabeled monoclonal antibody (539 visite)
Tumori (ISSN: 0300-8916, 0300-8916print, 0300-8916linking), 1991 Oct 31; 77(5): 449-451.
Impact Factor: 0.408
Dettagli Esporta in BibTeX Esporta in EndNote
Scala S, Pacelli R, Iaffaioli RV, Normanno N, Pepe S, Frasci G, Genua G, Tsuruo T, Tagliaferri P, Bianco AR
Reversal of adriamycin resistance by recombinant α-interferon in multidrug-resistant human colon carcinoma LoVo-doxorubicin cells (495 visite)
Cancer Res (ISSN: 0008-5472, 1538-7445, 1538-7445electronic), 1991 Sep 15; 51(18): 4898-4902.
Impact Factor: 8.426
Dettagli Esporta in BibTeX Esporta in EndNote
Camera L, Del Vecchio S, Petrillo A, Esposito G, Frasci G, Iaffaioli RV, Bianco AR, Salvatore M
Evaluation of therapeutic response using iodine-131-B72. 3 monoclonal antibody in patients with ovarian carcinoma (402 visite)
Eur J Nucl Med (ISSN: 0340-6997, 1619-7070, 1619-7089), 1991 Apr; 18(4): 269-273.
Impact Factor: 2.692
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Camera L, Petrillo A, Esposito G, Frasci G, Iaffaioli RV, Bianco AR, Salvatore M
Clinical studies with B72. 3 in ovarian cancer and probe-guided tumor localization (345 visite)
Nucl Med Biol (ISSN: 0883-2897, 0969-8051), 1991; 18(1): 85-87.
Impact Factor: 1.042
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Mansi L, Petrillo A, Camera L, Sofia M, Marra A, Carratú L, Salvatore M
Endobronchial administration of iodine-131 B72. 3 monoclonal antibody in patients with lung cancer (239 visite)
Eur J Nucl Med (ISSN: 0340-6997, 1619-7070, 1619-7089), 1991; 18(2): 129-132.
Impact Factor: 2.692
Dettagli Esporta in BibTeX Esporta in EndNote
Valenza V, Maussier ML, D'Errico G, Lemmo GF, Frontera D, Ferrante A, Saletnich I, Valli A, Quarantelli M
Cancer of the pancreas and the periampullary region: The usefulness of tumor marker products with the monoclonal antibody technique (241 visite)
J Nucl Med Allied Sci (ISSN: 0392-0208), 1990 Oct; 34(4SUPPL.): 131-134.
Impact Factor: 1.91
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Reynolds JC
NONUNIFORM DISTRIBUTION OF RADIOLABELED MONOCLONAL-ANTIBODY IN TUMOR (218 visite)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1990 Jul; 31(7): 1252-1252.
Impact Factor: 3.491
Dettagli Esporta in BibTeX Esporta in EndNote
Pezzino V, Papa V, Trischitta V, Brunetti A, Goodman PA, Treutelaar MK, Williams JA, Maddux BA, Vigneri R, Goldfine ID
Human insulin receptor radioimmunoassay: Applicability to insulin-resistant states (216 visite)
Am J Physiol Endocrinol Metab (ISSN: 0002-9513), 1989 Sep; 257(3): N/D-N/D.
Impact Factor: 3.116
Dettagli Esporta in BibTeX Esporta in EndNote
Trischitta V, Wong KY, Brunetti A, Scalisi R, Vigneri R, Goldfine ID
Endocytosis, recycling, and degradation of the insulin receptor. Studies with monoclonal antireceptor antibodies that do not activate receptor kinase (287 visite)
Jbc Papers (ISSN: 0021-9258, 1083-351x, 0021-9258linking), 1989 Mar 25; 264(9): 5041-5046.
Impact Factor: 6.963
Dettagli Esporta in BibTeX Esporta in EndNote
d'Onofrio G, Menichella G, Zini G, Rumi C, Pierelli L, Quarantelli M, Puggioni PL, Mango G
Lymphocyte subset counting by immunoperoxidase using an automated routine hematologic analyzer (334 visite)
Haematologica (ISSN: 0390-6078, 0006-4971, 0006-6497), 1989 Mar; 74(2): 137-142.
Impact Factor: 2.56
Dettagli Esporta in BibTeX Esporta in EndNote
Reynolds JC, Del Vecchio S, Sakahara H, Lora ME, Carrasquillo JA, Neumann RD, Larson SM
ANTI-MURINE ANTIBODY RESPONSE TO MOUSE MONOCLONAL ANTIBODIES CLINICAL FINDINGS AND IMPLICATIONS (501 visite)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897), 1989; 16(2): 121-125.
Impact Factor: 1.042
Dettagli Esporta in BibTeX Esporta in EndNote
Salvatore M, Lastoria S, Del Vecchio S, Mansi L
Detection of colon cancer with radiolabelled monoclonal antibodies (267 visite)
Nucl Med Biol (ISSN: 0883-2897, 0969-8051), 1989; 16(2): 103-104.
Impact Factor: 1.042
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Reynolds JC
DETERMINATION OF ANTIGEN CONCENTRATION AND DISTRIBUTION IN HUMAN TUMORS THE QUANTITATIVE AUTORADIOGRAPHIC APPROACH (259 visite)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897), 1989; 16(2): 143-145.
Impact Factor: 1.042
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Reynolds JC, Carrasquillo JA, Blasberg RG, Neumann RD, Lotze MT, Bryant GJ, Farkas RJ, Larson SM
Local distribution and concentration of intravenously injected 131I-9. 2. 27 monoclonal antibody in human malignant melanoma (275 visite)
Cancer Res (ISSN: 0008-5472, 1538-7445, 1538-7445electronic), 1989; 49(10): 2783-2789.
Impact Factor: 8.426
Dettagli Esporta in BibTeX Esporta in EndNote
DEL VECCHIO S, MANSI L, GAGLIARDI N, PETRILLO A, SOFIA M, CARRATU L, SALVATORE M
INTRABRONCHIAL ADMINISTRATION OF IODINE-131 B72. 3 MONOCLONAL ANTIBODY IN PATIENTS WITH LUNG CANCER (254 visite)
Eur J Nucl Med (ISSN: 0340-6997, 1619-7070, 1619-7089), 1988; 14(5-6): N/D-N/D.
Impact Factor: 2.692
Dettagli Esporta in BibTeX Esporta in EndNote
Del Vecchio S, Reynolds JC, Blasberg RG, Neumann RD, Carrasquillo JA, Hellström I, Larson SM
Measurement of local Mr 97, 000 and 250, 000 protein antigen concentration in sections of human melanoma tumor using in vitro quantitative autoradiography (449 visite)
Cancer Res (ISSN: 0008-5472, 1538-7445, 1538-7445electronic), 1988; 48(19): 5475-5481.
Impact Factor: 8.426
Dettagli Esporta in BibTeX Esporta in EndNote
69 Records (64 escludendo Abstract e Conferenze).
Impact factor totale: 271.125 (256.635 escludendo Abstract e Conferenze).
Impact factor a 5 anni totale: 273.524 (258.245 escludendo Abstract e Conferenze).
Impact factor totale: 271.125 (256.635 escludendo Abstract e Conferenze).
Impact factor a 5 anni totale: 273.524 (258.245 escludendo Abstract e Conferenze).
Last modified by Ultima modifica di Annamaria Sandomenico on in data Thursday 08 April 2021, 7:13:02
79 views visite. Last view on Ultima visita in data Friday 23 April 2021, 15:20:23